Physician

Rajesh Alla, M.D.

According to 2025 Medicare claims, Rajesh Alla, M.D. (NPI: 1154462224) practices nephrology in the Davenport-Moline-Rock Island, IA-IL market, with the plurality of this provider's patient population coming from Rock Island, IL. This provider's primary affiliated billing organization is RENALCARE ASSOCIATES, S.C. (NPI: 1649300377; TIN: 370995483) and primary practice location at 61265-6898. Alla is affiliated with the IRCCO (ACO ID: A2619), OSF Healthcare System (ACO ID: A3289), Genesis Accountable Care Organization, LLC. (ACO ID: A4799), SBL accountable care organization (ACO ID: A5147), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Alla's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 662 traditional Medicare patients, billed 2,961 HCPCS/CPT codes, and received $195,686 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 5,796 prescription claims across 855 beneficiaries totaling $687,842 in drug costs, led by Farxiga (Dapagliflozin Propanediol). 2021 DME data shows 29 claims. Open Payments data shows 1 records totaling $14. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $468,412 to $195,686. Similarly, Part D prescription costs have moved from a higher plateau to a lower plateau, from $738,753 to $687,842. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,233	22,064	$468,412
2016	948	17,614	$331,253
2017	1,031	12,072	$368,381
2018	1,122	3,216	$330,300
2019	982	2,639	$292,805
2020	1,106	2,624	$300,494
2021	919	2,339	$291,724
2022	751	2,247	$271,728
2023	705	1,927	$224,458
2024	662	2,961	$195,686

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	775	5,346	$738,753
2016	865	6,364	$744,988
2017	809	4,928	$886,879
2018	862	5,688	$625,288
2019	864	6,203	$468,869
2020	903	5,931	$336,329
2021	877	5,719	$341,101
2022	817	5,608	$334,503
2023	824	5,341	$431,432
2024	855	5,796	$687,842

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	80	$8,043
2017	N/R	47	$1,325
2018	N/R	14	$226
2019	N/R	69	$12,959
2020	N/R	74	$10,851
2021	N/R	29	$4,754
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	82	101	$117
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	78	180	$89
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	88	229	$58
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	444	888	$50
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	480	1,049	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	371	21,985	$409,969
Jardiance	Empagliflozin	132	7,682	$143,657
Auryxia	Ferric Citrate	12	540	$22,102
Lanthanum Carbonate	Lanthanum Carbonate	12	420	$8,835
Sevelamer Carbonate	Sevelamer Carbonate	22	1,680	$8,229

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$14	NXSTAGE MEDICAL, INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rajesh Alla, M.D.?

Tedicare shows public-source Medicare data for Rajesh Alla, M.D. (NPI 1154462224), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rajesh Alla, M.D. have ACO affiliation data?

Rajesh Alla, M.D. is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619), OSF Healthcare System (MSSP, ACO ID A3289), Genesis Accountable Care Organization, LLC. (MSSP, ACO ID A4799), SBL accountable care organization (MSSP, ACO ID A5147), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Rajesh Alla, M.D.?

Rajesh Alla, M.D. is linked to RENALCARE ASSOCIATES, S.C. (billing NPI 1649300377) in the available physician profile data.

Does Rajesh Alla, M.D. have Open Payments data?

Rajesh Alla, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.